73,500 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Purchased by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. bought a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 73,500 shares of the company’s stock, valued at approximately $1,959,000. Hussman Strategic Advisors Inc. owned 0.26% of Castle Biosciences as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. R Squared Ltd acquired a new position in Castle Biosciences in the fourth quarter valued at approximately $42,000. Quest Partners LLC boosted its position in shares of Castle Biosciences by 54.4% during the third quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock worth $123,000 after buying an additional 1,522 shares during the period. US Bancorp DE boosted its position in shares of Castle Biosciences by 1,889.2% during the third quarter. US Bancorp DE now owns 4,615 shares of the company’s stock worth $132,000 after buying an additional 4,383 shares during the period. Point72 DIFC Ltd acquired a new position in shares of Castle Biosciences during the third quarter worth approximately $140,000. Finally, Assetmark Inc. boosted its position in shares of Castle Biosciences by 16.8% during the third quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock worth $149,000 after buying an additional 748 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Lake Street Capital boosted their target price on Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Scotiabank upped their price target on Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a report on Wednesday, November 6th. KeyCorp upped their price target on Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Stephens reaffirmed an “overweight” rating and issued a $41.00 price target on shares of Castle Biosciences in a report on Thursday, January 2nd. Finally, Robert W. Baird upped their price target on Castle Biosciences from $37.00 to $39.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $40.29.

Castle Biosciences Trading Up 1.8 %

Castle Biosciences stock opened at $27.19 on Thursday. The company’s fifty day simple moving average is $27.65 and its 200-day simple moving average is $29.22. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 12 month low of $16.97 and a 12 month high of $35.84. The stock has a market cap of $761.59 million, a P/E ratio of 135.96 and a beta of 0.91.

Insider Buying and Selling

In related news, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total value of $221,613.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Derek J. Maetzold sold 986 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $28.03, for a total transaction of $27,637.58. Following the sale, the insider now directly owns 80,818 shares of the company’s stock, valued at approximately $2,265,328.54. The trade was a 1.21 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,771 shares of company stock worth $886,112. Corporate insiders own 7.20% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.